PRECEPT – PRostatE CancEr Prognosis and Treatment

CHIEF INVESTIGATOR

A/Prof Niall Corcoran, Clinician Researcher, Department of Surgery, The University of Melbourne

COLLABORATING INSTITUTIONS	TYPE/ROLE
University of Melbourne	LEAD INSTITUTE
Walter and Eliza Hall Institute of Medical Research	COLLABORATOR
Cambridge University Hospital	COLLABORATOR
Cancer Sciences, University of Manchester	COLLABORATOR
Dana-Farber Cancer Institute	COLLABORATOR
Department of Medical Oncology, Monash Health	COLLABORATOR
Ontario Institute for Cancer Research	COLLABORATOR
School of Medicine, Faculty of Health at Deakin University	COLLABORATOR
School of Medicine, University of Sydney	COLLABORATOR
South Australian Health & Medical Research Insitute	COLLABORATOR
The Institute of Cancer Research	COLLABORATOR
South Australian Health & Medical Research Insitute	COLLABORATOR
Peter MacCallum Cancer Centre	COLLABORATOR
South West Warrnambool Hospital	COLLABORATOR
La Trobe University	COLLABORATOR

GRANT

3 year (2019-2022) $4m grant from the Prostate Cancer Research Alliance, an Australian Government and Movember Foundation Collaboration

SHARE ON SOCIAL MEDIA

This research program aims to:

1. Develop a tissue and blood test that will predict the future risk of progression in men with prostate cancer at the time of diagnosis.
2. Develop new ‘curative’ treatments in patients with high risk disease, starting with two clinical studies using novel agents to investigate if treatment effects can be improved.
3. Develop new tests for DNA markers that predict how tumours will respond to treatment and using those results to help individualise patient treatment according to their specific tumour type to maximise treatment effect.

Danny Park, Bernie Pope and Chol Hee Jung are all working on the genomic aspects of this project.

October 2020 update from the VCCC

Cancer research embraces a shared vision | Victorian Comprehensive Cancer Centre

Learning that you have cancer can be a confronting and frightening experience, and the variation in prostate cancer treatment options can be particularly confusing for men, their families, and carers. VCCC consumers are assisting researchers to understand the impacts of a diagnosis on those affected and how tests and treatments can be improved.

Consumer advisors with direct experience with prostate cancer, long and successful commercial careers, and life and family experience have proved to be a genuine asset to the PRECEPT project team, including Professor Maarten IJzerman. The way in which consumers have been included in the study development provides a good model for others.

The ProstatE CancEr Prognosis and Treatment project (PRECEPT) involves genomics, immunotherapy, and health services research to establish genomic biomarker-based tests for shared decision-making in treatment. Collaborators have set out to develop a tissue and blood test that will predict the future risk of progression in men with prostate cancer at the time of diagnosis; new curative treatments in patients with high-risk disease; and new tests that will predict how patients will respond to treatment. Read more.